HOUSTON, March 2, 2021 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology, today
announced that it has selected RESONIC™ as the brand name for the
Rapid Acoustic Pulse (RAP) Device.
The RAP device received FDA 510(k) clearance for its tattoo
indication in May 2019 and its
cellulite indication in February
2021. The initial launch of the RESONIC brand for both
indications is expected in Q2 2021.
"We are excited to begin establishing Soliton's presence in the
aesthetics industry with a new brand that brings to life our
groundbreaking acoustic technology. We expect RESONIC to be a
gamechanger in the removal of tattoos and improvement in cellulite
appearance and believe the RESONIC brand captures our innovation;
giving patients the opportunity to reimagine themselves without
their tattoo or with greatly improved cellulite. We look forward to
commercializing the FDA-cleared RESONIC device in the second
quarter of 2021," said Brad Hauser,
Soliton CEO and President.
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product,
RESONIC™ will use rapid pulses of acoustic shockwaves as an
accessory to lasers for the removal of unwanted tattoos and the
treatment of cellulite. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse (RAP) device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods. The
Company also believe the technology will provide the first
non-invasive acoustic technology to target the underlying causes of
dimples and ridges in cellulite. Soliton is investigating potential
additional capabilities of the RAP technology. The device is
currently cleared in the United
States only for use in tattoo removal and cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation to successfully treat
patients for tattoo removal and cellulite and to launch our product
during the second quarter of 2021. These statements relate to
future events, future expectations, plans and prospects. Although
Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Soliton has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in our most recently filed Form 10-K and updated from
time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements contained
in this release speak only as of its date. Soliton undertakes no
obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-selects-resonic-as-brand-name-for-fda-cleared-rapid-acoustic-pulse-device-301237893.html
SOURCE Soliton, Inc.